These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39160538)

  • 1. Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.
    Halik A; Tilgner M; Silva P; Estrada N; Altwasser R; Jahn E; Heuser M; Hou HA; Pratcorona M; Hills RK; Metzeler KH; Fenwarth L; Dolnik A; Terre C; Kopp K; Blau O; Szyska M; Christen F; Krönke J; Vasseur L; Löwenberg B; Esteve J; Valk PJM; Duchmann M; Chou WC; Linch DC; Döhner H; Gale RE; Döhner K; Bullinger L; Yoshida K; Damm F
    J Hematol Oncol; 2024 Aug; 17(1):70. PubMed ID: 39160538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of
    Abbas HA; Ayoub E; Sun H; Kanagal-Shamanna R; Short NJ; Issa G; Yilmaz M; Pierce S; Rivera D; Cham B; Wing S; Li Z; Hammond D; Jabbour E; Borthakur G; Garcia-Manero G; Andreeff M; Daver N; Kadia T; Konopleva M; DiNardo C; Ravandi F
    Leuk Lymphoma; 2022 Dec; 63(13):3105-3116. PubMed ID: 36089905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.
    Rücker FG; Schlenk RF; Bullinger L; Kayser S; Teleanu V; Kett H; Habdank M; Kugler CM; Holzmann K; Gaidzik VI; Paschka P; Held G; von Lilienfeld-Toal M; Lübbert M; Fröhling S; Zenz T; Krauter J; Schlegelberger B; Ganser A; Lichter P; Döhner K; Döhner H
    Blood; 2012 Mar; 119(9):2114-21. PubMed ID: 22186996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype.
    Xu N; Lai YY; Chen WM; Jiang H; Wang Y; Wang X; Zhao XS; Huang XJ; Jiang Q; Qin YZ
    Int J Lab Hematol; 2022 Oct; 44(5):892-899. PubMed ID: 35505580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Niparuck P; Police P; Noikongdee P; Siriputtanapong K; Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Siriboonpiputtana T
    Diagn Pathol; 2021 Oct; 16(1):100. PubMed ID: 34717674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
    Becker H; Pfeifer D; Ihorst G; Pantic M; Wehrle J; Rüter BH; Bullinger L; Hackanson B; Germing U; Kuendgen A; Platzbecker U; Döhner K; Ganser A; Hagemeijer A; Wijermans PW; Döhner H; Duyster J; Lübbert M
    Ann Hematol; 2020 Jul; 99(7):1551-1560. PubMed ID: 32504186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q).
    Zhang R; Kim YM; Wang X; Li Y; Lu X; Sternenberger AR; Li S; Lee JY
    Int J Med Sci; 2015; 12(9):719-26. PubMed ID: 26392809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients.
    Kayser S; Feszler M; Krzykalla J; Schick M; Kramer M; Benner A; Thol F; Platzbecker U; Müller-Tidow C; Ho AD; Ehninger G; Heuser M; Schlenk RF; Thiede C; Röllig C; Krämer A
    Eur J Haematol; 2017 Dec; 99(6):544-552. PubMed ID: 28940816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
    Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
    Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia.
    Kao HW; Liang DC; Wu JH; Kuo MC; Wang PN; Yang CP; Shih YS; Lin TH; Huang YH; Shih LY
    Neoplasia; 2014 Jun; 16(6):481-8. PubMed ID: 25022553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia.
    Alfayez M; Issa GC; Patel KP; Wang F; Wang X; Short NJ; Cortes JE; Kadia T; Ravandi F; Pierce S; Assi R; Garcia-Manero G; DiNardo CD; Daver N; Pemmaraju N; Kantarjian H; Borthakur G
    Leukemia; 2021 Mar; 35(3):691-700. PubMed ID: 32561839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4.
    Herold T; Metzeler KH; Vosberg S; Hartmann L; Jurinovic V; Opatz S; Konstandin NP; Schneider S; Zellmeier E; Ksienzyk B; Graf A; Krebs S; Blum H; Cristina Sauerland M; Büchner T; Berdel WE; Wörmann BJ; Mansmann U; Hiddemann W; Bohlander SK; Spiekermann K; Greif PA
    Genes Chromosomes Cancer; 2017 Jan; 56(1):75-86. PubMed ID: 27636548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia.
    Stasik S; Eckardt JN; Kramer M; Röllig C; Krämer A; Scholl S; Hochhaus A; Crysandt M; Brümmendorf TH; Naumann R; Steffen B; Kunzmann V; Einsele H; Schaich M; Burchert A; Neubauer A; Schäfer-Eckart K; Schliemann C; Krause S; Herbst R; Hänel M; Frickhofen N; Noppeney R; Kaiser U; Baldus CD; Kaufmann M; Rácil Z; Platzbecker U; Berdel WE; Mayer J; Serve H; Müller-Tidow C; Ehninger G; Bornhäuser M; Schetelig J; Middeke JM; Thiede C;
    Blood Adv; 2021 Sep; 5(17):3279-3289. PubMed ID: 34459887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.
    Ohgami RS; Ma L; Merker JD; Gotlib JR; Schrijver I; Zehnder JL; Arber DA
    Mod Pathol; 2015 May; 28(5):706-14. PubMed ID: 25412851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.
    Hou HA; Kuo YY; Liu CY; Chou WC; Lee MC; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    Blood; 2012 Jan; 119(2):559-68. PubMed ID: 22077061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia.
    Nahi H; Lehmann S; Bengtzen S; Jansson M; Möllgård L; Paul C; Merup M
    Leuk Lymphoma; 2008 Mar; 49(3):508-16. PubMed ID: 18297528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).
    Paschka P; Du J; Schlenk RF; Gaidzik VI; Bullinger L; Corbacioglu A; Späth D; Kayser S; Schlegelberger B; Krauter J; Ganser A; Köhne CH; Held G; von Lilienfeld-Toal M; Kirchen H; Rummel M; Götze K; Horst HA; Ringhoffer M; Lübbert M; Wattad M; Salih HR; Kündgen A; Döhner H; Döhner K
    Blood; 2013 Jan; 121(1):170-7. PubMed ID: 23115274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of
    Liu H; Shi Y; Tao S; Li Y; Wang C; Yu L
    Hematology; 2023 Dec; 28(1):2223866. PubMed ID: 37313982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
    Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
    J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.